Sale!
Awaiting product image

The Top 25 IVD Companies: Revenue Performance, Products, Strategies, Market Activities

$2,000.00 – $4,000.00

SKU: KLI15498064 Categories: , Pages: 225

Description

IVD Market Top 25 Companies: Revenue Performance, Products, Competitive Activity

IVD Market Top 25 Companies presents advancements in in vitro diagnostics (IVD) by the Top 25 firms in the industry and provides an overview of the most recent trends and developments.   Companies included are:

  •  Alere Inc.
  •  Arkray
  •  Beckman Coulter / Danaher
  •  Becton Dickinson
  •  Bio-Rad Laboratories
  •  bioMérieux
  •  Cepheid / Danaher
  •  Danaher Corp. (including Radiometer A/S)
  •  Grifols
  •  Hologic
  •  Illumina
  •  Instrumentation Laboratory / Werfen
  •  LabCorp, Laboratory Corporation of America
  •  Luminex
  •  Ortho Clinical Diagnostics
  •  PerkinElmer
  •  Qiagen N.V.
  •  Quest Diagnostics
  •  Quidel
  •  Roche Diagnostics (including Ventana Medical Systems)
  •  Philips
  •  Siemens Healthineers
  •  Sysmex Corporation
  •  Thermo Fisher Scientific

 The report examines the major manufacturers in the IVD industry in terms of

  • Recent Revenue History and Commentary
  • Business Overview 
  • Revenue in Selected Test Segments
  • Current and New Products
  • Competitive Activity: M&A, Partnerships and Other Moves

In addition to the in-depth company information, the report examines market trends, including those involving gene editing, liquid biopsy, microbiome, patient service center revival, partnering and acquisitions, direct to consumer genomics, and growing IVD company activity in Asia, Africa, and Latin America.

IVD Market Top 25 Companies also presents highlights of IVD industry developments as demonstrated by a selection of small and niche firms in 2016 and the first half of 2017, which are preparing for the future with the development of next generation systems, informatics to help labs manage and retrieve test data, new infectious disease diagnostics, and gene-based oncology tests for targeted therapeutics.
 
This report on the advancements in in vitro diagnostics at the hands of the major companies provides an overview of the most recent trends and developments in the industry.  It is not a comprehensive review of the diagnostics industry in general.
Clinical laboratory technology has changed dramatically in the past few years, due to the publication of the human genome project and advances in functional genomics, bioinformatics, miniaturization and microelectronics.  Not five years ago it would have been almost inconceivable to see research technologies such as genome sequencing and mass spectroscopy play a pivotal role in improving lab medicine.  Their influence is felt in personalized medicine, inherited diseases, pathogen detection, antibiotic resistance testing, blood banking and much more to come. 
The top five majors continue to bring innovations to clinical diagnostics.  However, of particular interest in the past year or so are the efforts made by companies such as Bio-Rad Laboratories, Illumina and Thermo Fisher Scientific.  These and other companies are translating their portfolio of research-based molecular solution to clinical tools.
A review of the advancements reported by the major IVD companies included in this report shows innovations in CRISPR gene editing that is being adapted to the diagnosis of problematic diseases and the development of new therapeutics.

Table of Contents

1: EXECUTIVE SUMMARY

Table 1-1: Exchange Rate Fluctuations, 2012–2016

MARKET TRENDS

Gene Editing

Liquid Biopsy

Table 1-2: Selected Liquid Biopsy Innovations

Microbiome

Patient Service Center Revival

IVD Companies Mix and Match

Table 1-3: Selected Menu Expansion by Partnering and Acquisitions

Direct to the Consumer Genomics

Looking to the East

2: TOP 25 IVD COMPANIES – CORPORATE PROFILES

ABBOTT DIAGNOSTICS

Table 2-1: Abbott Recent Revenue History, 2013-2017 ($ million)

Table 2-2: Abbott’s Revenue in Selected Test Segments, 2013-2017 ($ million) (Histology (Vysis), Chem/Immuno, Hematology,

Molecular, Point of Care, Diabetes)

2016/2017 Business Highlights

Alere Acquisition Update

Core Lab

Coagulation

Infectious Diseases – Molecular

Diabetes

iSTAT Business

Companion Testing

Zika

ALERE INC.

Table 2-3: Alere Recent Revenue History, 2013-2017 (total Dx, $ million)

Table 2-4: Alere Revenue by IVD Test Segment, 2013-2017 ($ million) (Cardiac Markers, Infectious Diseases, Toxicology, Diabetes- Arriva, Other)

Innovation Milestones

Abbott Acquisition Update

Diabetes

HIV

Alere Reader

Coagulation

Molecular POC

Market Expansion

ARKRAY

Recent Revenue History

Molecular

Immunoassays

Urinalysis

Diabetes

BECKMAN COULTER, INC. / DANAHER

Table 2-5: Beckman Coulter, Inc. / Danaher Recent Revenue History, 2011-2017 ($ million, estimated)

Table 2-6: Beckman Coulter’s Revenue in Selected Test Segments ($ million, estimated), 2011-2016 (Routine Chemistry, Immunoassays, Hematology, Microbiology)

Hematology

Clinical Chemistry

Immunoassays

Coagulation

Lab Management

Flow Cytometry

Research

BECTON, DICKINSON AND COMPANY (BD)

Table 2-7: Becton, Dickinson and Company (BD) Recent Revenue History, 2013-2017 (diagnostic systems, $ million)

Table 2-8: BD’s Revenue in Selected IVD Test Segments ($ million, estimated), 2013 (Molecular, Microbiology ID/AST, Microbiology media, Rapid Tests, Blood Culture)

Table 2-9: BD’s Flow Cytometry Revenue ($ million, estimated), 2012-2015

Cytology

BD Max Molecular

ID/AST

POC Veritor

Mass Spectrometry

Blood Collection

Flow Cytometry

Licensing

BIO-RAD LABORATORIES, INC

Table 2-10: Bio-Rad Laboratories Recent Revenue History, 2013-2017 (all diagnostics, $ million, estimated)

Table 2-11: Bio-Rad’s Revenue in Selected Product Segments ($ million, estimated), 2012-2016 (Quality Control, Immunoassays, Microbiology (all), Blood Bank)

Quality Control

Blood Bank

Infectious Diseases – Molecular

Immunoassays

Liquid Biopsy

Microbiome

Droplet Digital PCR

Sequencing

BIOMÉRIEUX INC.

Table 2-12: bioMérieux Recent Revenue History, 2013-2017 (Total IVDs, $ million)

Table 2-13: bioMérieux’s Revenue in Selected IVD Test Segments ($ million), 2013-2017 (Microbiology, Immunoassays, Molecular, FilmArray)

Traditional Microbiology

Blood Culture

Immunoassays

Mass Spectrometry

Platelet Safety

Sequencing

Sequencing – Sample Preparation, Molecular

Data Analysis

BioFire Diagnostics Business

CEPHEID / DANAHER

Table 2-14: Cepheid Recent Revenue History, 2013-2017 (clinical product sales, $ million)

Tuberculosis

Microbiology

Influenza

POC HIV

Cancer

DANAHER CORPORATION

Table 2-15: Danaher Corp. Recent Revenue History, 2014-2017 ($ million – diagnostics – most recent years for which data is available, estimated)

Table 2-16: Danaher’s Revenue in Selected Business Segments, 2013-2017 ($ million, estimated)

For 2016 vs 2015, Danaher Reported . . .

Beckman Coulter

Radiometer

Leica Biosystems

Cepheid

Radiometer A/S Profile

Table 2-17: Radiometer Recent Revenue History, 2012-2016 (estimated, core products, $ million)

Radiometer, POC

Radiometer, Critical Care

Radiometer, Immunoassays

GRIFOLS

Recent Revenue History

Table 2-18: Grifols Diagnostic Product Revenues, 2012-2017 ($ million, estimated) (Core, Blood Screen, Total)

2016 Summary as Reported by Grifols

Blood Transfusion Business

Blood Bank CLIA Lab

Coagulation

Acquisitions and Collaborations

HOLOGIC, INC.

Table 2-19: Hologic Recent Revenue History, 2013-2017 (total Dx; $ million)

Table 2-20: Hologic’s Revenue in Selected Segments ($ million), 2013-2017 (HPV (legacy), ThinPrep/cytology, Molecular, Blood Bank)

Panther Molecular System

Panther Fusion

Blood Bank – Zika Virus

Collaboration

ILLUMINA

Table 2-21: Illumina Recent Revenue History, 2013-2017 ($ million – not all revenues are for clinical products and services [estimated])

Reported 2016 Summary

Sequencing

Microarrays

Project Firefly

Grail Liquid Biopsy

Forensic Medicine

Prenatal Testing Business

INSTRUMENTATION LABORATORY (IL) / WERFEN

Table 2-22: Instrumentation Laboratory (IL) Recent Revenue History, 2012-2016 ($ million)

Table 2-23: IL’s Revenue in Selected Product Segments ($ million), 2012-2016 (Coagulation, Critical Care)

Expansion

Coagulation

Critical Care

Information Technology

LABCORP, LABORATORY CORPORATION OF AMERICA

Table 2-24: LabCorp Recent Revenue History, 2013-2017 ($ millions)

LabCorp Buys Sequenom

Diagnostics Services

Prenatal

Retail Outlets

LUMINEX CORPORATION

Table 2-25: Luminex Recent Revenue History, 2013-2016 ($ million)

Assay Development

Verigene Business

Business Expansion

ORTHO CLINICAL DIAGNOSTICS (OCD)

Table 2-26: Ortho Clinical Diagnostics (OCD) Recent Revenue History, 2012-2016 ($ million, estimated) .. 122

Table 2-27: OCD’s Revenue in Selected Test Segments ($ million), 2015 (Immunoassays, Chemistry, Blood Grouping)

Blood Bank

Core Lab / Immunoassays

Lab Automation

Connectivity

PERKINELMER, INC. (PE)

Table 2-28: PerkinElmer Recent Revenue History, 2014-2017 ($ million, estimated)

Diagnostics

Sequencing

Histology

Prenatal Business

Lab Services

Expansion

QIAGEN N.V.

Table 2-29: QIAGEN Recent Revenue History, 2013-2017 ($ million)

Table 2-30: QIAGEN Molecular IVD Product Revenues ($ million), 2013-2017 (HPV, TB, Other Molecular, Total IVD)

Tuberculosis

Companion Diagnostics

Digital Sequencing

Bioinformatics

Liquid Biopsy

Cervical Cancer

Transplant medicine

Forensic

Expansion

QUEST DIAGNOSTICS

Table 2-31: Quest Diagnostics Recent Revenue History, 2010-2016 ($ million)

Highlights from 2016

Diagnostic Services

Oncology

Infectious Diseases

Prenatal and Women’s Health

Neurology

Retail / Direct to Consumer

QUIDEL CORPORATION

Table 2-32: Quidel Recent Revenue History, 2013-2016 ($ million)

Immunoassays

The Solana Business

ROCHE DIAGNOSTICS

Table 2-33: Roche Diagnostics Recent Revenue History, 2011-2017 ($ millions)

Table 2-34: Roche’s Revenue in Selected Test Segments, 2013-2016 ($ millions, estimated) (Chemistry/Immuno, Diabetes, Molecular, Histology)

Hematology

Immunoassays

Global Access Program for HIV

Molecular Expansion

Core Molecular

Diabetes

Coagulation

cobas Liat System – POC

HPV

Blood Bank

Transplant Medicine

Cancer Companion Testing

Prenatal

Liquid Biopsy

Roche’s Ventana Medical Systems Inc.

Table 2-35: Ventana Recent Revenue History, 2013-2017 ($ million)

PHILIPS

Histology

Cancer Genomics

Patient Monitoring

Point of Care

Wearable Self Monitor

SIEMENS HEALTHINEERS

Table 2-36: Siemens Recent Revenue History, 2012-2015 (total IVD; $ million)

Table 2-37: Siemens’ IVD Product Sales in Selected Test Segments, 2012-2015 ($ million) (Chemistry/Immunoassays, Coagulation,

Hematology, Molecular, Urinalysis, Blood Gases)

Business Expansion

Lab Automation

Coagulation

Immunoassays

Molecular

POC Connectivity

SYSMEX CORPORATION

Table 2-38: Sysmex Recent Revenue History, 2012-2017 ($ million)

Table 2-39: Sysmex’s Product Sales in Selected Test Segments, 2013-2016 ($ million) (Hematology, Coagulation, Urinalysis)

Business Expansion

Hematology

Coagulation

Urinalysis

Forging New Markets

Sysmex Inostics

THERMO FISHER SCIENTIFIC INC.

Table 2-40: Thermo Fisher Recent Revenue History, 2013-2016 (clinical diagnostics, $ million)

Table 2-41: Thermo Fisher Product Sales in Selected Test Segments, 2015-2016 ($ million) (Clinical products, Immunoassays, Microbiology, Histology)

Immunoassays

Microbiology

Molecular Test Business

Oncology Companion Diagnostics

Zika

Transplant Medicine

Quality Control IT

Point of Care

Mass Spectrometry

Forensic

Expansion

Research

3:  OTHER IVD COMPANY NOTABLE

EVENTS

Table 3-1: Selected New Products

Related products

The Worldwide Market for Laboratory-Developed Tests: Services (Labs Performing...The Global Market for Medical Devices, 8th Edition (40 Specific Device Markets...